Artificial pancreas can effectively control type 1 diabetes in children over 6 years of age

clinical trial at four pediatric diabetes centers in the United States found that a new artificial pancreatic system that automatically monitors and regulates blood sugar levels in patients with type 1 diabetes in six-year-olds is safe and effective. The trial was funded by the National Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The results were published August 26 in the New England Journal of Medicine."Less than one in five children with type 1 diabetes is able to successfully keep their blood sugar within a healthy range, which can seriously affect long-term health and quality of life," said Guillermo Arreaza-Rubín, M.D., director of the NIDDK Diabetes Technology Program and a project scientist for the study. Earlier studies have shown that the systems tested in this study are safe and effective for people 14 years and older. Now, the experiment shows us that the system can be used with young children in real-world environments.the artificial pancreas, also known as closed-loop control, is a "all-in-one" diabetes management system that uses a continuous blood glucose monitor (CGM) to track blood sugar levels and automatically deliver insulin using an insulin pump when needed. The system delivers insulin through multiple injections per day or pumps controlled by patients or caregivers to replace dependence that relies on fingertips or Dekang for testing.The study recruited 101 children between the ages of 6 and 13 and divided them into experimental groups using new artificial pancreatic systems or control groups using standard CCM and independent insulin pumps. Check-in and data collection is conducted every two weeks for a period of four months.Instruct study participants to continue their daily lives so that researchers can best understand how the system works in typical routines for children.
study found that young people who used an artificial pancreatic system had a 7 percent increase in blood sugar during the day and a 26 percent increase in night control compared to the control group. Night control is especially important for people with type 1 diabetes, as severe uncontrolled hypoglycemia can lead to seizures, coma and even death. The total time range target for the artificial pancreas reflects an improvement of nearly 11%, which means an additional 2.6 hours per day.
Barbara Davis, a professor of pediatrics at the University of Colorado Aurora(CU) Children's Diabetes Center in New York. Dr Paul Wadwa said: "This study is impressive for improving blood sugar control, especially on all-night nights, to let parents and caregivers know that their children are safer and that they sleep better at night. Artificial pancreas technology can reduce the number of times children and their families stop to care for people with diabetes. Instead, children can be more focused. During

, 16 adverse events occurred in the artificial pancreas group, all classified as mild, mainly problems with insulin pump equipment. Three events occurred in the control group. There were no cases of severe hypoglycemia or diabetic ketoacidosis during the study period.“ For decades, NIDDK has been funding research and technology development to create a user-friendly automated device that reduces the ongoing burden of type 1 diabetes, from finger rod and insulin injections to insulin dose calculations and continuous monitoring, while improving diabetes control outcomes and preventing short- and long-term complications of the disease," arreaza-Rubín said.“ The artificial pancreas is the culmination of these years of effort, and it is exciting to see how this technology can be used in people with type 1 diabetes and their families, and hopefully everyone will benefit from future diabetic children.The artificial pancreatic technology Control-IQ system used in this study has an insulin pump that uses a mathematical model that automatically adjusts insulin doses based on human glucose monitoring information and is programmed based on advanced control algorithms. The technology originated from a system originally developed at the University of Virginia (UVA) in Charlottesville and was funded by NIDDK.The four-month study is part of a series of trials conducted in the International Diabetes Closed Loop Study (iDCL). In addition to CU and UVA, the study sites include Stanford University School of Medicine in Palo Alto, California, and the Jaeb Center for Health Research at Yale University School of Medicine in New Haven, Connecticut.
based on data from the iDCL trial, Tandem Diabetes Care has been licensed by the U.S. Food and Drug Administration for the use of the Control-IQ system in 6-year-olds.
"As we continue to look for ways to treat type 1 diabetes, providing safe and effective artificial pancreatic techniques for children with type 1 diabetes, such as those used in this study, is an important step in improving the quality of life and managing the diseases of these young people," said Griffin J. Dr. P. Rogers said.
iDCL study is one of four major research efforts funded by NIDDK through the Special Statutory Funding Program for Type 1 Diabetes to test and improve advanced artificial pancreatic systems. The study, along with other upcoming results, is looking at factors including safety, efficacy, user friendliness, participants' physical and emotional health, and costs.

the study was funded by NIDDK and Tandem Diabetes, Inc. Tandem offers experimental closed-loop systems used in trials, system-related supplies, including Decon Continuous Blood Glucose Monitor and Roche Glucose Meter, as well as technical expertise. (cyy123.com)original source: Any pancreas effectively controls type 1 diabetes in children age 6 and up